Other languages Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
4.37 ^USD	+4.92%		-29.40%	-38.71%

06-20	HC Wainwright Adjusts Price Target on Shattuck Labs to $16 From $28, Maintains Buy Rating	MT
06-17	Citigroup Adjusts Shattuck Labs Price Target to $9 From $10, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shattuck Labs, Inc. Announces Committee Appointments	06-11
Shattuck Labs Says FDA Grants Orphan Drug Designation to Leukemia Drug; Shares Rise	06-10
Shattuck Labs, Inc. Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration for SL-172154 for the Treatment of Acute Myeloid Leukemia	06-10
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress	05-14
Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02
Shattuck Labs, Inc. Announces Board Appointments	03-04
Sector Update: Health Care Stocks Rising Late Afternoon	03-01
Sector Update: Health Care Stocks Advance Friday Afternoon	03-01
Shattuck Labs Shares Rise as Q4 Net Loss Narrows	03-01
Shattuck Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29
Shattuck Labs, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29
Shattuck Labs Collaborates With Ono Pharmaceutical to Develop Fusion Proteins	02-14
Shattuck Labs, Inc. Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	02-13
Shattuck Labs Insider Sold Shares Worth $250,000, According to a Recent SEC Filing	01-16
Shattuck Labs, Inc. Files Initial Topline Dose-Exp Expansion Data from Its Ongoing Phase 1A/B Clinical Trial of Sl-172154 in Frontline Tp53m Aml and Tp53m Aml Patients	12-21
Shattuck Labs Shares Soar as Blood Cancer Therapy Trial Yields 79% Objective Response Rate	12-13
Top Midday Gainers	12-13
Fed Meeting Awaited as Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Wednesday	12-13
Top Premarket Gainers	12-13
Shattuck Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Other languages

Filters